Surveillance and prevention of hepatocellular carcinoma

  • M. Colombo
Conference paper
Part of the Falk Symposium book series (FASS, volume 160)


Prevention of hepatocellular carcinoma (HCC) is feasible since the tumour occurs in the context of well-recognized, potentially preventable risk factors1. Strategies of prevention differ in the various geographical areas, in accordance with the geographical variability of risk factors. In this chapter primary prevention means preventing the onset of cancer, by lowering an individual’s exposure to known risk factors such as hepatitis viruses, alcohol or progressive liver disease. Secondary prevention aims at counteracting HCC severity, i.e. reducing tumour recurrence after eradication. In patients chronically exposed to risk factors for HCC, surveillance is the only practical approach to improve treatment outcome2. Surveillance is the process by which diagnostic tests and recall procedures have been standardized to provide a clinically meaningful definition of early cancer1. Both prevention and surveillance are expected to reduce HCC-related mortality2.


Chronic Hepatitis Cirrhotic Patient Dysplastic Nodule Liver Cell Dysplasia Hepat Itis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bruix J, Sherman M. Management of hepatocsillular carcinoma. Heputology. 2003;43:1208–36.Google Scholar
  2. 2.
    Bruck J, Sherman M, Llovet JM et al. Clinical management of hepatoceilular carcinoma. Conclusions of the Barcelona — 2000 EASL Conference. J Hepatol. 2001;35:421–30.CrossRefGoogle Scholar
  3. 3.
    Colombo M, de Franchis R, Del Ninno E et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675–80.PubMedGoogle Scholar
  4. 4.
    Sun Z, Lu P, Gail MH et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable aflatoxin metabolite M1. Hepatology. 1999;30:379–83.PubMedCrossRefGoogle Scholar
  5. 5.
    Makino Y, Shiraki K, Sugimoto K et al. Histological features of cirrhosis with hepatitis C virus for prediction of hepatocellular carcinoma development; a prospective study. Anticancer Res. 2000;20:3709–16.PubMedGoogle Scholar
  6. 6.
    Donato MF, Arosio A, Del Ninno E et al. Liver cell proliferation predicts hepatocellular carcinoma and long-term survival in patients with compensated cirrhosis. Hepatology. 2001;34:523–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Borzio M, Bruno S, Roncalli M et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology. 1995;108:812–17.PubMedCrossRefGoogle Scholar
  8. 8.
    Kobayashi M, Ikeda K, Hosaka T et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer. 2006;106:636–47.PubMedCrossRefGoogle Scholar
  9. 9.
    Park NY, Roncalli M. Large liver cell dysplasia: a controversial entity. J Hepatol. 2006;45:734–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–14.PubMedCrossRefGoogle Scholar
  11. 11.
    Ganne-Carriè N, Chastang C, Chapel F et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in western patients with cirrhosis. Hepatology. 1996;23:1112–18.PubMedCrossRefGoogle Scholar
  12. 12.
    Velazquez RF, Rodriguez M, Navascues CA et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003;37:520–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Marrero JA, Su GL, Wei W et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Borzio M, Borzio F, Macchi R et al. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. J Hepatol. 1994;20:117–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Buscarini L, Fornari F, Bolondi L et al. Ultrasound-guided fine-needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. A retrospective study on 2091 biopsies. J Hepatol. 1990;11:344–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Kojiro M. The evolution of pathologic features of hepatocellular carcinoma. In: Tabor E, editor. Viruses and Liver Cancer: Perspectives in Medical Virology. Amsterdam: Elsevier. 2002:113–22.CrossRefGoogle Scholar
  17. 17.
    Fracanzani AL, Burdick L, Borzio M et al. Contrast-enhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology. 2001;34:1109–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Bolondi L, Gaiani S, Celli N et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology. 2005;42:27–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Takayasu K, Muramatsu Y, Mizuguchi Y et al. CT evaluation of the progression of hypoattenuating nodular lesions in virus-related chronic liver disease. Am J Roentgenol. 2006;187:454–63.CrossRefGoogle Scholar
  20. 20.
    Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis. 2005;25:133–42.PubMedCrossRefGoogle Scholar
  21. 21.
    Nam SW, Park JY, Ramasamy A et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology. 2005;42:809–18.PubMedCrossRefGoogle Scholar
  22. 22.
    Llovet JM, Chen Y, Wurmbach E et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131:1758–67.PubMedCrossRefGoogle Scholar
  23. 23.
    Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol. 2006;44:798–805.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–22.PubMedGoogle Scholar
  25. 25.
    Drummond MF, O’Brien B, Stoddart GL et al. Cost-effectiveness analysis. In: Drummond MF, O’Brien B, Stoddart GL, Torrance GW, editors. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. New York: Oxford University Press, 1997:96–138.Google Scholar
  26. 26.
    Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of sereening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101:422–34.PubMedCrossRefGoogle Scholar
  27. 27.
    Arguedas MR, Chen VK, Eloubeidi MA et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679–90.PubMedCrossRefGoogle Scholar
  28. 28.
    Lin OS, Keeffe EB, Sanders GD et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;482:251–9.CrossRefGoogle Scholar
  30. 30.
    Spada E, Mele A, Ciccozzi M et al. Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. Dig Liver Dis. 2001;33:778–84.PubMedCrossRefGoogle Scholar
  31. 31.
    Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol. 2006;45:607–16.PubMedCrossRefGoogle Scholar
  33. 33.
    Wang JS, Shen X, He X et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People’s Republic of China. J Natl Cancer Inst. 1999;91:347–54.PubMedCrossRefGoogle Scholar
  34. 34.
    Egner PA, Wang JB, Zhu YR et al. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci USA. 2001;98:14601–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–74.PubMedCrossRefGoogle Scholar
  36. 36.
    Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferonalpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34:306–13.PubMedCrossRefGoogle Scholar
  37. 37.
    Brunetto MR, Oliveri F, Coco B et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002:36:263–70.PubMedCrossRefGoogle Scholar
  38. 38.
    Lampertico P, Del Ninno E, Viganò M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003;37:756–63.PubMedCrossRefGoogle Scholar
  39. 39.
    Di Marco V, Marzano A, Lampertico P et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40:883–91.PubMedCrossRefGoogle Scholar
  40. 40.
    Lampertico P, Viganò M, Manenti E et al. Five years of sequential Lam to Lam+Adv therapy suppresses HBV replication in most HBeAg negative cirrhotics, preventing decompensation but not hepatocellular carcinoma. J Hepatol. 2006;43:S38.CrossRefGoogle Scholar
  41. 41.
    Liaw YF, Sung JJY, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.PubMedCrossRefGoogle Scholar
  42. 42.
    Craxi A, Cammà C. Prevention of hepatocellular carcinoma. Clin Liver Dis. 2005;9:329–46.PubMedCrossRefGoogle Scholar
  43. 43.
    Kashiwagi K, Furusyo N, Kubo N et al. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother. 2003;9:333–40.PubMedCrossRefGoogle Scholar
  44. 44.
    Shiratori Y, Ito Y, Yokosuka O et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105–14.PubMedGoogle Scholar
  45. 45.
    Yoshida H. Arakawa Y, Sata M et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123:483–91.PubMedCrossRefGoogle Scholar
  46. 46.
    Yu ML, Lin SM, Chuang WL et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11:985–94.PubMedGoogle Scholar
  47. 47.
    Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–87.PubMedCrossRefGoogle Scholar
  48. 48.
    Muto Y, Moriwaki H, Ninomiya M et al. prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med. 1996;334:1561–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Lau WY, Leunt TWT, Ho SKW et al. Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 1999;353:797–801.PubMedCrossRefGoogle Scholar
  50. 50.
    Boucher E, Corbinais S, Rolland Y et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology. 2003;38:1237–41.PubMedCrossRefGoogle Scholar
  51. 51.
    Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356:802–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Mazzaferro V, Romito R, Schiavo M et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer and Falk Foundation e.V. 2008

Authors and Affiliations

  • M. Colombo
    • 1
  1. 1.First Division of Gastroenterology Fondazione IRCCS MaggioreHospital Policlinico, Mangiagalli and Regina Elena University of MilanMilanItaly

Personalised recommendations